更新于：2024-12-14
Triptorelin acetate
醋酸曲普瑞林
更新于：2024-12-14
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-09-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C66H86N18O15 |
InChIKeyHPPONSCISKROOD-OYLNGHKZSA-N |
CAS号140194-24-7 |
序列信息
Sequence Code 15218785
来源: *****
关联
48
项与 醋酸曲普瑞林 相关的临床试验Study on Human Bioequivalence of Triprerelin Acetate for Injection
注射用醋酸曲普瑞林人体生物等效性研究
一项多中心、开放、单臂 III 期临床试验：评估注射用醋酸曲普瑞林微球治疗儿童中枢性性早熟的有效性和安全性
100 项与 醋酸曲普瑞林 相关的临床结果
登录后查看更多信息
100 项与 醋酸曲普瑞林 相关的转化医学
登录后查看更多信息
100 项与 醋酸曲普瑞林 相关的专利（医药）
登录后查看更多信息
65
项与 醋酸曲普瑞林 相关的文献（医药）2024-06-30Annals of pediatric endocrinology & metabolism
Long-term efficacy of a triptorelin 3-month depot in girls with central precocious puberty
Article
作者: Lee, Kee-Hyoung ; Kang, Eungu ; Nam, Hyo-Kyoung ; Chung, Lindsey Yoojin ; Gwag, Si-Hwa ; Kim, Yu Jin ; Park, Kyu Hyun ; Rhie, Young-Jun
Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
2024-04-01Reproduction in domestic animals = Zuchthygiene
Article
作者: Camillo, Francesco ; Moroni, Rebecca ; Berti, Giovanni ; Fanelli, Diana ; Maltinti, Saverio ; Rota, Alessandra ; Panzani, Duccio
Abstract:
Most of the northern hemisphere donkey breeds are faced with the risk of extinction, thus donkey reproduction is considered an emerging branch of theriogenology, and the management of artificial insemination and induction of ovulation is a crucial point in setting up preservation protocols. For four consecutive cycles, six jennies' ovarian activity was routinely monitored; an ultrasound examination was performed daily from the evidence of a follicle diameter ≥27 mm until ovulation. Upon reaching a follicular diameter ≥32 ± 2 mm (Hour 0), oestrous jennies were treated alternatively with 0.1 mg triptorelin acetate, sc, (TRIP), 0.4 mg/sc of buserelin acetate (BUS) or saline, sc, (CTRL) and examined ultrasonographically at Hours 14, 24, 38, 42, 48, 62 and every 24 h until ovulation. Induction of ovulation was considered successful if ovulation occurred from 24 to 48 h after treatment. 11/12 cycles resulted in ovulation for TRIP and 12/12 for BUS and CTRL groups, respectively. Mean ± SD ovulation time after treatment was 37.3 ± 8.3, 47.1 ± 21.0 and 66.8 ± 25.9 h for BUS, TRIP and CTRL, respectively (p = .0032). Ovulation rates between h24 and h48 were 10/12 (83.3%) for both TRIP/BUS and 2/12 (16.7%) for CTRL, respectively (p = .003). Buserelin and triptorelin‐treated jennies had a 25 times higher probability to ovulate between Hours 24 and 48 than controls (p = .003), while there were no jenny and cycle effects on the ovulatory rate. The results of this study show how triptorelin successfully induced ovulation in jennies, like other GnRH analogues previously evaluated.
2024-04-01Clinical endocrinology
Peak serum luteinising hormone cut‐off during gonadotropin‐releasing hormone analogue test for diagnosing central precocious puberty was lower in girls with obesity as compared with girls with normal weight
Article
作者: Mahachoklertwattana, Pat ; Sakornyutthadej, Natee ; Wankanit, Somboon ; Poomthavorn, Preamrudee
Abstract:
Objective:
Serum luteinising hormone (LH) concentration has been reported to be lower in girls with overweight and obesity (OW/OB) as compared with girls with normal weight (NW). This study aimed to evaluate peak serum LH concentration during gonadotropin‐releasing hormone analogue (GnRHa) test in girls with OW/OB and NW who had central precocious puberty (CPP) and to determine peak serum LH cut‐off for diagnosing CPP in girls with OW/OB.
Design, Patients and Measurements:
Medical records of 971 girls with premature breast development who underwent subcutaneous GnRHa (100 µg of triptorelin acetate) test were reviewed. All girls were classified as either CPP or premature thelarche. All of them were further classified into two groups according to their body mass index as NW and OW/OB groups for each Tanner stage.
Results:
There were 634 and 337 girls in NW and OW/OB groups, respectively. CPP was diagnosed in 600 girls (249 had Tanner stage II and 351 had Tanner stage III). There were no differences in peak serum LH concentrations between CPP girls with NW and OW/OB. Peak serum LH cut‐off of 5 IU/L (the current widely used cut‐off) had a sensitivity and a specificity of 75% and 90%, respectively in NW group. Peak serum LH cut‐off for CPP diagnosis was lower at 4 IU/L in the OW/OB group with greater sensitivity and specificity of 86% and 93%, respectively. The results were reproducible for each Tanner stage of breasts.
Conclusion:
Lower peak serum LH cut‐off to 4 IU/L for diagnosing CPP in girls with OW/OB should be considered to avoid underdiagnosis of the condition.
100 项与 醋酸曲普瑞林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫内膜异位症 | 中国 | 2024-09-26 | |
| 性早熟 | 澳大利亚 | 2015-03-04 | |
| 前列腺癌 | 中国 | 2004-09-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV感染 | 临床2期 | 德国 | 2018-09-19 | |
| HIV感染 | 临床2期 | 瑞典 | 2018-09-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 148 | 蓋鑰範蓋網窪範醖遞醖(憲淵壓襯醖窪範網醖憲) = 觸鬱夢製襯鑰蓋顧選艱 獵鹽鬱願鏇蓋鹹簾製艱 (糧鏇願繭糧鹽選憲繭範 ) | - | 2023-09-21 | |||
临床3期 | 86 | 鑰網齋糧鬱淵網淵夢顧(積艱築鑰鏇獵鏇鹹淵願) = 夢餘製網觸餘鏇襯醖構 齋鑰範鹽齋鑰網膚繭範 (鬱窪餘鹽鹹窪襯衊網餘, 蓋糧餘鬱鹹廠願餘壓築 ~ 衊積糧鹽構窪選網觸鑰) 更多 | - | 2016-07-25 | |||
N/A | - | TPM-TRP conjugates | 積構廠願衊積憲糧鹽艱(艱醖製鹹鏇餘製淵齋網) = 廠餘鏇窪壓蓋網繭憲鹽 鹹廠願廠糧鏇鹽製簾齋 (顧膚憲淵廠顧遞積壓鏇 ) | - | 2016-07-15 | ||
積構廠願衊積憲糧鹽艱(艱醖製鹹鏇餘製淵齋網) = 簾糧憲願構蓋齋鹹衊鹹 鹹廠願廠糧鏇鹽製簾齋 (顧膚憲淵廠顧遞積壓鏇 ) | |||||||
N/A | 乳腺癌 新辅助 | - | 膚鬱觸衊艱遞窪蓋積願(遞憲艱顧網夢膚鏇範網) = 顧顧蓋鏇構願獵遞鹹膚 獵餘顧製淵糧網製窪鹽 (鏇壓網網顧鑰艱蓋窪遞 ) | - | 2008-05-20 | ||
膚鬱觸衊艱遞窪蓋積願(遞憲艱顧網夢膚鏇範網) = 選蓋廠鬱顧衊簾壓鬱壓 獵餘顧製淵糧網製窪鹽 (鏇壓網網顧鑰艱蓋窪遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用